A Phase 1, Open-Label, 2-Arm, Fixed-Sequence Study to Evaluate the Potential Effects of Multiple Doses of Rifampin (CYP3A4 Inducer) and Clarithromycin (CYP3A4 Inhibitor) on the Single Dose Pharmacokinetics of Deflazacort in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Deflazacort (Primary) ; Clarithromycin; Rifampicin
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Marathon Pharmaceuticals
- 22 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 12 Nov 2014 New trial record